Please assess the completion status of the following clinical trial:

Trial Title: Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* infants with symptomatic hemangiomas~Exclusion Criteria:~* asthma~* diabetes~* hypertension~* hypotension~* hypoglycemia~* liver failure~* previous treatment for hemangiomas

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- propranolol for treatment of hemangiomas (Type: EXPERIMENTAL): Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
- Prednisolone (Type: ACTIVE_COMPARATOR): Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.

Based on this trial design, predict the completion outcome and termination type (if applicable).